VBI Vaccines Inc said on Monday it had entered into an agreement with Canada to develop a potential vaccine for COVID-19 by 2022 through mid-stage trials conducted exclusively in the country.
Canada will contribute around 75% of the U.S.-based company’s development costs and C$55.9 million ($42.2 million) for the project.
VBI Vaccines said last month that together with the National Research Council Canada it was investigating the vaccine candidate, VBI-2900, in preclinical trials.
![Receive the latest medical news and health information delivered to you every Sunday.](https://globalnews.ca/wp-content/themes/shaw-globalnews/images/skyline/healthiq.jpg)
Get weekly health news
As per the agreement, signed last week, the company’s Ottawa-based unit is obligated to complete the vaccine development in or before the first quarter of 2022.
![Click to play video: 'Ottawa signs 2 new COVID-19 vaccine deals for Canada'](https://i1.wp.com/media.globalnews.ca/videostatic/news/tpgh1rq07x-gesq6ntu4k/0831_mlc.jpg?w=1040&quality=70&strip=all)
There are currently no approved vaccines for COVID-19, but around 38 vaccines are being tested in humans around the world.
- Jasper wildfire: Alberta government to look into mixed messaging in evacuation orders
- Jasper National Park wildfire evacuees told to take roundabout route back to Alberta
- ‘A big green light to cut’: What to expect from the Bank of Canada this week
- New and used vehicle supply is surging. Here’s how prices are reacting
Comments